Evidence map›Paper›PMID 39443629›Full record

ArticleScientific reports2024

Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study.

Christiaan M de Bloeme, Robin W Jansen, Liesbeth Cardoen, Sophia Göricke, Sabien van Elst, Jaime Lyn Jessen, Aparna Ramasubramanian, Alison H Skalet, Audra K Miller, Philippe Maeder and 19 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Definition of parameters and thresholds to detect MYCN amplification in retinoblastomas.Virchows Archiv : an international journal of pathology · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Christiaan M de BloemeEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands. c.debloeme@amsterdamumc.nl.
Robin W JansenEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Liesbeth CardoenEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Sophia GörickeEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Sabien van ElstEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Jaime Lyn JessenImpact Genetics - Dynacare, Ontario, Canada.
Aparna RamasubramanianDepartment of Ophthalmology, Children's Wisconsin, Wisconsin, United States.
Alison H SkaletCasey Eye Institute Oregon Health & Science University , Portland, United States.
Audra K MillerCasey Eye Institute Oregon Health & Science University , Portland, United States.
Philippe MaederEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Ogul E UnerCasey Eye Institute Oregon Health & Science University , Portland, United States.
G Baker HubbardEmory Eye Center Ocular Oncology Service, Atlanta, United States.
Hans GrossniklausEmory Eye Center Ocular Oncology Service, Atlanta, United States.
H Culver BoldtDepartment of Ophthalmology, University of Iowa Hospitals & Clinics, Iowa, United States.
Kim E NicholsDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, United States.
Rachel C BrennanDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, United States.
Saugata SenDepartment of Radiology and Imaging Sciences, Tata Medical Center, Kolkata, India.
Mériam KoobEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Selma SirinEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Hervé J BrisseEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Paolo GalluzziEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Charlotte J DommeringCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Matthijs CysouwCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Ronald BoellaardCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Josephine C DorsmanCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Annette C MollCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Marcus C de JongEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
Pim de GraafEuropean Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
European Retinoblastoma Imaging Collaboration

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MYCN-amplified RB1 wild-type (MYCN

Indexed as

Magnetic Resonance ImagingN-Myc Proto-Oncogene ProteinRetinoblastomaRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesCase-Control StudiesChildChild, PreschoolDiagnosis, DifferentialFemaleHumansInfantMachine LearningMaleMutationRadiomicsMYCN protein, humanN-Myc Proto-Oncogene ProteinRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesMRI; radiomicsMYCN-amplificationRetinoblastoma

Identifiers

PMID39443629
PMCPMC11499940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.